Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Neurocrine Switzerland GmbH
- Study ID
- NCT07536269
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Congenital Adrenal Hyperplasia
Eligibility Criteria
- Sex
- ALL
- Age
- 3 Months - 47 Months
- Healthy Volunteers
- Not accepted
Interventions
- Crinecerfont — DRUGOral solution
Study Details
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.
Key Dates
- First listed
- Apr 17, 2026
- Start date
- Jul 1, 2026
- Status verified
- Sep 2026
- Primary completion
- Mar 31, 2028
- Completion
- Mar 31, 2028
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: CrinecerfontParticipants with CAH will receive crinecerfont.
Primary Outcome Measure
Number of Participants With Treatment-emergent Adverse Events (TEAE) [ Time Frame: Day 1 up to 28 weeks ]
Central Contacts
- Neurocrine Medical Information Call Center1-877-641-3461
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Neurocrine Clinical Site | San Francisco | California | 94143 | - |
| Neurocrine Clinical Site | Hartford | Connecticut | 06106 | - |
| Neurocrine Clinical Site | Atlanta | Georgia | 30329 | - |
| Neurocrine Clinical Site | Chicago | Illinois | 60618 | - |
| Neurocrine Clinical Site | Indianapolis | Indiana | 46202 | - |
| Neurocrine Clinical Site | Ann Arbor | Michigan | 48109 | - |
| Neurocrine Clinical Site | Minneapolis | Minnesota | 55454 | - |
| Neurocrine Clinical Site | Philadelphia | Pennsylvania | 19104 | - |
| Neurocrine Clinical Site | Dallas | Texas | 75235 | - |
| Neurocrine Clinical Site | Seattle | Washington | 98101 | - |
Find similar trials in San Francisco, CA
Related Studies
- A Trial of Lu AG13909 in Participants With Congenital Adrenal HyperplasiaPHASE1/PHASE2 · Recruiting · H. Lundbeck A/S · Ann Arbor, Michigan
- An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal HyperplasiaPHASE2 · Recruiting · Crinetics Pharmaceuticals Inc. · Minneapolis, Minnesota
- A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaPHASE3 · Recruiting · Crinetics Pharmaceuticals Inc. · Los Angeles, California
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)PHASE2/PHASE3 · Recruiting · Crinetics Pharmaceuticals Inc. · San Francisco, California